- Page 2 and 3: PREFACEThe Antimicrobial Use Guidel
- Page 4 and 5: Antimicrobial Cost Table (Cost info
- Page 6 and 7: Summary of Antibiotic Order Form: S
- Page 8: LUNGS/PULMONARYCommunity-Acquired P
- Page 13 and 14: ADEFOVIR - nonformulary at UWHCUsua
- Page 15 and 16: AMPHOTERICIN B LIPOSOMAL (AmBisome
- Page 17 and 18: Indications1. Treatment of acute, u
- Page 19 and 20: Indications1. Serious infections wi
- Page 21 and 22: 4. Complicated skin infections caus
- Page 23 and 24: can still be successfully treated w
- Page 25 and 26: Pediatrics:** (not approved for chi
- Page 27 and 28: Drug InteractionsClarithromycin is
- Page 29 and 30: Indications1. Oropharyngeal candidi
- Page 31 and 32: For use in patients with reported p
- Page 33 and 34: Pediatrics:** 40 mg/kg/day PO in di
- Page 35 and 36: 6. Prophylaxis of fungal infections
- Page 37 and 38: • Astemizole (contraindicated)•
- Page 39 and 40: Primaxin ® , meropenem and doripen
- Page 41 and 42: Indications1. Blastomyces dermatiti
- Page 43 and 44: 3. Pyelonephritis.4. Susceptible St
- Page 45 and 46: • Methyldopa - concurrent adminis
- Page 47 and 48: MICAFUNGINInfectious Disease approv
- Page 49 and 50: NAFCILLINNafcillin and oxacillin ar
- Page 51 and 52: OXACILLINOxacillin and nafcillin ar
- Page 53 and 54: PENTAMIDINEUsual DoseAdult: Treatme
- Page 55 and 56: CommentsFood and/or acid is require
- Page 57 and 58: RALTEGRAVIR (Isentress ® ) - nonfo
- Page 59 and 60:
RIFAMPINUse of rifampin for injecti
- Page 61 and 62:
RIFAXIMIN (Xifaxan ® )Usual doseAd
- Page 63 and 64:
TELITHROMYCINUsual DoseAdult: 800 m
- Page 65 and 66:
TOBRAMYCINUsual DoseAdult: 2.5 mg/k
- Page 67 and 68:
VALACYCLOVIRUsual DoseAdult: 1 g TI
- Page 69 and 70:
VORICONAZOLEInfectious Disease appr
- Page 71 and 72:
APPENDIX A: PREVENTION OF INFECTIVE
- Page 73 and 74:
GastrointestinalLIKELYPATHOGENSANTI
- Page 75 and 76:
CardiothoracicLIKELYPATHOGENSANTIMI
- Page 77 and 78:
NeurosurgicalLIKELYPATHOGENS• ANT
- Page 79 and 80:
TraumaticwoundStaphylococcus aureus
- Page 81 and 82:
scored)Ethambutol Tablet (100 mg, 4
- Page 83 and 84:
Table 2 Suggested pyrazinamide dose
- Page 85 and 86:
BLOOD CULTURE FOR FILAMENTOUS FUNGI
- Page 87 and 88:
2.3 Recent animal data and some rec
- Page 89 and 90:
3.0 There is no proven role for the
- Page 91 and 92:
References:1. Mora-Duarte J. Betts
- Page 93 and 94:
Amph/AMPHOTERICIN B LIPID COMPLEX C
- Page 95 and 96:
Appendix F: UWHC Guideline for Medi
- Page 97 and 98:
Table 1: Medications Approved for P
- Page 99 and 100:
E. References1. Ramirez JA. Antibio
- Page 101 and 102:
1.3.8 Sub-therapeutic response to d
- Page 103 and 104:
nephrotoxicity. A retrospective coh
- Page 105 and 106:
7.3. Patients on a regular dialysis
- Page 107 and 108:
38. Matzke GR, McGory RW, Halstenso
- Page 109 and 110:
4.5.1.1 To assist with the resoluti
- Page 111 and 112:
4.0 Type 4: Cellular immune-mediate
- Page 113 and 114:
1.2.3.5.1. Prescriber should be con
- Page 115 and 116:
1.2 Anaphylaxis medications should
- Page 117 and 118:
Order for beta-lactam antibioticPen
- Page 119 and 120:
Infection Treatment CommentsOtitis
- Page 121 and 122:
Community-AcquiredPneumonia 21,22-P
- Page 123 and 124:
References1. National Institute for
- Page 125 and 126:
Appendix L: Child-Pugh Grading of L
- Page 127 and 128:
Table 1. GI Surgical Prophylaxis Re
- Page 129 and 130:
For adults recovering from intraabd
- Page 131 and 132:
abdominal infection, with the excep
- Page 133 and 134:
Appendix N: Antimicrobial Duration
- Page 135 and 136:
Intra-abdominal Infection 5Complica
- Page 137 and 138:
PulmonaryCryptococcalOrgan Transpla
- Page 139 and 140:
University of Wisconsin Hospital an
- Page 141 and 142:
To address 3-hour infusions of mero
- Page 143 and 144:
Compatibility:Piperacillin/Tazobact
- Page 145 and 146:
UWHC Guidelines for the Use of Dapt
- Page 147 and 148:
4.0 Dose adjustment is required in
- Page 149 and 150:
12.0 Dosing during continuous veno-